The deletion polymorphism of the enzyme UGT2B17 is known to correlate with the level of the testosterone to epitestosterone (T/E) ratio in urine specimen. Due to the importance of the T/E ratio to detect testosterone abuse in doping analysis, a PCR-ELISA system (Genotype® UGT test, AmplexDiagnostics) was established to identify the UGT2B17 phenotype in urine samples. Epidemiological investigations in a set of 674 routine doping controls (in- and out-of-competition) resulted in 22.8% homozygote gene-deleted and 74.5% UGT2B17-positive athletes. The validated test system has shown to be robust and sensitive: in only 18 cases (2.7%) isolation of cell material from urine failed.

Following hydrolysis of glucuronidated conjugates, steroids were analyzed as bis-TMS derivatives by gas chromatography-mass spectrometry (GC-MS), for example, testosterone (T) and epitestosterone (E). Additionally, isotope ration mass spectrometry (IRMS) analysis and luteinizing hormone (LH) measurement were applied. Mean T/E ratios significantly correlated with the UGT2B17 phenotype (del: T/E 0.9; pos: 1.7), however the values did not differ as distinctive as reported in previous studies. Additionally, the T/E ratios in the gene-deleted group did not show a normal curve of distribution (median of T/E 0.5). Obviously, beside the UGT2B17 deletion further influences have to be taken into account, for example, polymorphisms or induction of other metabolizing enzymes. Our results indicate that the UGT2B17 polymorphism might be insufficient when utilized solely as a crucial parameter for individual interpretation of T/E in urine. Nevertheless, the detection of the UGT2B17-gene deletion in urine samples would provide additional information important for gathering evidence in analysis of steroids in doping control. Copyright © 2011 John Wiley & Sons, Ltd.

Supporting Information

References

1 J. Park, L. Chen, L. Ratnashinge. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 1473.
10.1158/1055-9965.EPI-06-0141
CASPubMedWeb of Science®Google Scholar
2 A.H. Karypidis, M. Olsson, S.O. Andersson, A. Rane, L. Ekström. Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate. Pharmacogenomics J. 2008, 8, 147.
10.1038/sj.tpj.6500449
CASPubMedWeb of Science®Google Scholar
3 N. Deshmukh, A. Petróczi, J. Barker, A.D. Székely, I. Hussain, D.P. Naughton. Potentially harmful advantage to athletes: a putative connection between UGT2B17 gene deletion polymorphism and renal disorders with prolonged use of anabolic androgenic steroids. Subst. Abuse Treat. Prev. Policy. 2010, 5, 7.
10.1186/1747-597X-5-7
PubMedWeb of Science®Google Scholar
4 S.R. Setlur, C.X. Chen, R.R. Hossain. Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostatecancer. Cancer Epidemiol. Biomarkers Prev. 2010, 19, 229.
10.1158/1055-9965.EPI-09-1018
CASPubMedWeb of Science®Google Scholar
5 M. Olsson, S. Lindström, B. Häggkvist, H.O. Adami, K. Bälter, P. Stattin, B. Ask, A. Rane, L. Ekström, H. Grönberg. The UGT2B17 gene deletion is not associated with prostate cancer risk. Prostate 2008, 68, 571.
10.1002/pros.20700
CASPubMedWeb of Science®Google Scholar
6 C.J. Gallagher, F.F. Kadlubar, J.E. Muscat, C.B. Ambrosone, N.P. Lang, P. Lazarus. The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case-control study in Caucasians. Cancer Detect. Prev. 2007, 31, 310.
10.1016/j.cdp.2007.07.005
CASPubMedWeb of Science®Google Scholar
7 J.Y. Park, J.P. Tanner, T.A. Sellers, Y. Huang, C.K. Stevens, N. Dossett, R.A. Shankar, B. Zachariah, R. Heysek, J. Pow-Sang. Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. Urology 2007, 70, 374.
10.1016/j.urology.2007.03.001
PubMedWeb of Science®Google Scholar
8 T. Kuuranne. Phase-II metabolism of androgens and its relevance for doping control analysis. Handb. Exp. Pharmacol. 2010, 195, 65.
10.1007/978-3-540-79088-4_3
CASPubMedGoogle Scholar
9 C.J. Jin, P.I. Mackenzie, J.O. Miners. The regio- and stereo-selectivity of C19 and C21 hydroxysteroid glucuronidation by UGT2B7 and UGT2B11. Arch. Biochem. Biophys. 1997, 341, 207.
10.1006/abbi.1997.9949
CASPubMedWeb of Science®Google Scholar
10 T. Kuuranne, M. Kurkela, M. Thevis, W. Schänzer, M. Finel, R. Kostiainen. Glucuronidation of anabolic androgenic steroids by recombinant human UDP-glucuronosyltransferases. Drug Metab. Dispos. 2003, 31, 1117.
10.1124/dmd.31.9.1117
CASPubMedWeb of Science®Google Scholar
11 T. Sten, I. Bichlmaier, T. Kuuranne, A. Leinonen, J. Yli-Kauhaluoma, M. Finel. UDP-glucuronosyltransferases (UGTs) 2B7 and UGT2B17 display converse specificity in testosterone and epitestosterone glucuronidation, whereas UGT2A1 conjugates both androgens similarly. Drug Metab. Dispos. 2009, 37, 417.
10.1124/dmd.108.024844
CASPubMedWeb of Science®Google Scholar
12 J. Jakobsson, L. Ekström, N. Inotsume, M. Garle, M. Lorentzon, C. Ohlsson, H.K. Roh, K. Carlström, A. Rane. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J. Clin. Endocrinol. Metab. 2006, 91, 687.
10.1210/jc.2005-1643
CASPubMedWeb of Science®Google Scholar
13 J.J. Schulze, J. Lundmark, M. Garle, I. Skilving, L. Ekström, A. Rane. Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J. Clin. Endocrinol. Metab. 2008, 93, 2500.
10.1210/jc.2008-0218
CASPubMedWeb of Science®Google Scholar
14 World Anti-Doping Agency (WADA). The 2011 Prohibited List, International Standard. Available at: http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/To_be_effective/WADA_Prohibited_List_2011_EN.pdf [18 September 2010].
Google Scholar
15 World Anti-Doping Agency (WADA). TD2004EAAS, version 1.0, technical document. Avilable at: http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-IS-Laboratories/WADA_TD2004EAAS_EN.pdf [13 August 2004].
Google Scholar
16 C. Saudan, N. Baume, N. Robinson, L. Avois, P. Mangin, M. Saugy. Testosterone and doping control. Br. J. Sports Med. 2006, 40(1), i21.
10.1136/bjsm.2006.027482
PubMedWeb of Science®Google Scholar
17 B.L. Coffman, C.D. King, G.R. Rios, T.R. Tephly. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab. Dispos. 1998, 26, 73.
CASPubMedWeb of Science®Google Scholar
18 D. Turgeon, J.S. Carrier, E. Lévesque, D.W. Hum, A. Bélanger. Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 2001, 142, 778.
10.1210/endo.142.2.7958
CASPubMedWeb of Science®Google Scholar
19 J.O. Miners, R.A. McKinnon, P.I. Mackenzie. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 2002, 181–182, 453.
10.1016/S0300-483X(02)00449-3
CASPubMedWeb of Science®Google Scholar
20 W. Wilson 3rd, F. Pardo-Manuel de Villena, B.D. Lyn-Cook, P.K. Chatterjee, T.A. Bell, D.A. Detwiler, R.C. Gilmore, I.C. Valladeras, C.C. Wright, D.W. Threadgill, D.J. Grant. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 2004, 84, 707.
10.1016/j.ygeno.2004.06.011
CASPubMedWeb of Science®Google Scholar
21 E. Strahm, P.E. Sottas, C. Schweizer, M. Saugy, J. Dvorak, C. Saudan. Steroid profiles of professional soccer players: An international comparative study. Br. J. Sports Med. 2009, 43, 1126.
10.1136/bjsm.2008.056242
CASPubMedWeb of Science®Google Scholar
22 P.E. Sottas, C. Saudan, C. Schweizer, N. Baume, P. Mangin, M. Saugy. From population- to subject-based limits of T/E ratio to detect testosterone abuse in elite sports. Forensic Sci. Int. 2008, 174, 166.
10.1016/j.forsciint.2007.04.001
CASPubMedWeb of Science®Google Scholar
23 U. Mareck, H. Geyer, G. Fusshöller, A. Schwenke, N. Haenelt, T. Piper, M. Thevis, W. Schänzer. Reporting and managing elevated testosterone/epitestosterone ratios-novel aspects after five years' experience. Drug Test. Analysis 2010, 2, 637.
10.1002/dta.234
CASPubMedWeb of Science®Google Scholar
24 J.J. Schulze, J. Lundmark, M. Garle, L. Ekström, P.E. Sottas, A. Rane. Substantial advantage of a combined Bayesian and genotyping approach in testosterone doping tests. Steroids 2009, 74, 365.
10.1016/j.steroids.2008.11.003
CASPubMedWeb of Science®Google Scholar
25 World Anti-Doping Agency (WADA). International Standard for Laboratories, version 6.0. 2009. Available at: http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-IS-Laboratories/WADA_Int.Standard_Laboratories_2009_EN.pdf [1January 2009].
Google Scholar
26 A. Juul, K. Sørensen, L. Aksglaede, I. Garn, E. Rajpert-De Meyts, I. Hullstein, P. Hemmersbach, A.M. Ottesen. A common deletion in the uridine diphosphate glucuronyltransferase (UGT) 2B17 gene is a strong determinant of androgen excretion in healthy pubertal boys. J. Clin. Endocrinol. Metab. 2009, 94, 1005.
10.1210/jc.2008-1984
CASPubMedWeb of Science®Google Scholar
27 A. Schuette. Molekulargenetische Untersuchungen der UGT2B17-Gendeletion an 100 Bayrischen Probanden, internship report. LMU Munich, Institute of Forensic Medicine, Munich, 2008, pp. 1–34.
Google Scholar

Citing Literature

Volume3, Issue10

October 2011

Pages 645-651

Epidemiological investigation of the UGT2B17 polymorphism in doping control urine samples and its correlation to T/E ratios

ABSTRACT

Supporting Information

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Epidemiological investigation of the UGT2B17 polymorphism in doping control urine samples and its correlation to T/E ratios

ABSTRACT

Supporting Information

References

Citing Literature

References

Related

Information